Assessing the utility of common arguments used in expert review of in silico predictions as part of ICH M7 assessments
Alex Cayley, Susanne Glowienke(Novartis (Switzerland)), Angela White(GlaxoSmithKline (United Kingdom)), Raphael Nudelman(Teva Pharmaceuticals (Israel)), Michelle Kenyon(Pfizer (United States)), Mirit Cohen‐Ohana(Teva Pharmaceuticals (Israel)), Alessandro Brigo(Roche (Switzerland)), Robert S. Foster(Canary Wharf Group (United Kingdom)), Alyssa Musso(Pfizer (United States)), Patricia Parris(Pfizer (United Kingdom)), Wolfgang Muster(Roche (Switzerland))
Cited by 6
Related Papers
OxyR
|Cell|2002|474
S-nitrosylation: spectrum and specificity
|Nature Cell Biology|2001|243
Drug Insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis
|Nature Clinical Practice Rheumatology|2008|197
The in vivo Pig-a assay: A report of the International Workshop On Genotoxicity Testing (IWGT) Workgroup
|Mutation Research/Genetic Toxicology and Environmental Mutagenesis|2014|156